5:58 PM
 | 
Mar 03, 2014
 |  BC Extra  |  Clinical News

Boehringer's Spiriva Respimat meets in asthma trial

Boehringer Ingelheim GmbH (Ingelheim, Germany) said once-daily Spiriva Respimat tiotropium as add-on therapy met the primary endpoint in the Phase III GraziaTinA-asthma trial of improving peak forced expiratory volume in one second (FEV1) within the first three hours of dosing at week...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >